ATHX:NSD-Athersys, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.57

Change

0.00 (0.00)%

Market Cap

USD 0.35B

Volume

0.02B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD79.98B 133.51 104.16
REGN Regeneron Pharmaceuticals, Inc

N/A

USD57.31B 15.31 11.96
BNTX BioNTech SE

N/A

USD51.30B -99,999.99 31.95
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD48.63B 17.91 12.34
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.06B 58.65 41.96
BGNE BeiGene, Ltd

N/A

USD29.61B N/A N/A
SGEN Seagen Inc

N/A

USD28.37B 43.61 39.21
GMAB Genmab A/S

N/A

USD28.05B 26.59 3.73
RPRX Royalty Pharma plc

N/A

USD26.73B 22.60 15.75
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD20.79B N/A N/A

ETFs Containing ATHX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.29% 39% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.29% 39% F 19% F
Trailing 12 Months  
Capital Gain -20.30% 34% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.30% 34% F 11% F
Trailing 5 Years  
Capital Gain -27.31% 40% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.31% 40% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain 11.89% 48% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.89% 48% F 55% F
Risk Return Profile  
Volatility (Standard Deviation) 39.62% 76% C 45% F
Risk Adjusted Return 30.00% 55% F 48% F
Market Capitalization 0.35B 47% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.01 20% F 17% F
Price / Cash Flow Ratio -5.64 39% F 68% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -310.59% 6% F 3% F
Return on Invested Capital -286.76% 3% F 2% F
Return on Assets -100.07% 3% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 14.61 10% F 4% F
Short Percent 12.06% 22% F 15% F
Beta -1.68 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector